KR20190110740A - 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 - Google Patents

신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 Download PDF

Info

Publication number
KR20190110740A
KR20190110740A KR1020180032554A KR20180032554A KR20190110740A KR 20190110740 A KR20190110740 A KR 20190110740A KR 1020180032554 A KR1020180032554 A KR 1020180032554A KR 20180032554 A KR20180032554 A KR 20180032554A KR 20190110740 A KR20190110740 A KR 20190110740A
Authority
KR
South Korea
Prior art keywords
dihydro
triazol
aminomethyl
fluoroprop
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020180032554A
Other languages
English (en)
Korean (ko)
Inventor
한태동
탁희재
김은경
최수빈
김동훈
박솔
정은혜
최현호
김태왕
주미경
하나리
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Priority to KR1020180032554A priority Critical patent/KR20190110740A/ko
Priority to KR1020207029749A priority patent/KR20200123846A/ko
Priority to AU2019237342A priority patent/AU2019237342B2/en
Priority to EP19770858.9A priority patent/EP3768663A4/en
Priority to CN201980020750.6A priority patent/CN111886227B/zh
Priority to CA3093051A priority patent/CA3093051A1/en
Priority to PCT/IB2019/052276 priority patent/WO2019180644A1/en
Priority to JP2020550099A priority patent/JP7322052B2/ja
Priority to US16/359,984 priority patent/US10562865B2/en
Priority to TW108109844A priority patent/TWI825079B/zh
Priority to ARP190100712A priority patent/AR115006A1/es
Publication of KR20190110740A publication Critical patent/KR20190110740A/ko
Priority to US16/721,020 priority patent/US10899719B2/en
Priority to US17/104,557 priority patent/US11492335B2/en
Priority to JP2023121661A priority patent/JP2023134824A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020180032554A 2018-03-21 2018-03-21 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 Pending KR20190110740A (ko)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020180032554A KR20190110740A (ko) 2018-03-21 2018-03-21 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
JP2020550099A JP7322052B2 (ja) 2018-03-21 2019-03-20 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物
US16/359,984 US10562865B2 (en) 2018-03-21 2019-03-20 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
EP19770858.9A EP3768663A4 (en) 2018-03-21 2019-03-20 NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES, OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS THEREOF
CN201980020750.6A CN111886227B (zh) 2018-03-21 2019-03-20 新颖的芳基或杂芳基三唑酮衍生物或其盐、或含有它们的药物组合物
CA3093051A CA3093051A1 (en) 2018-03-21 2019-03-20 Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
PCT/IB2019/052276 WO2019180644A1 (en) 2018-03-21 2019-03-20 Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
KR1020207029749A KR20200123846A (ko) 2018-03-21 2019-03-20 신규한 아릴 또는 헤테로아릴 트리아졸론 유도체 또는 그의 염, 또는 그를 포함하는 제약 조성물
AU2019237342A AU2019237342B2 (en) 2018-03-21 2019-03-20 Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
TW108109844A TWI825079B (zh) 2018-03-21 2019-03-21 新穎的芳基或雜芳基三唑酮衍生物或其鹽或包含彼等之醫藥組合物
ARP190100712A AR115006A1 (es) 2018-03-21 2019-03-21 Derivados de aril o heteroaril triazolona o sales de los mismos o composiciones farmacéuticas que comprenden los mismos
US16/721,020 US10899719B2 (en) 2018-03-21 2019-12-19 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
US17/104,557 US11492335B2 (en) 2018-03-21 2020-11-25 Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
JP2023121661A JP2023134824A (ja) 2018-03-21 2023-07-26 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180032554A KR20190110740A (ko) 2018-03-21 2018-03-21 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
KR20190110740A true KR20190110740A (ko) 2019-10-01

Family

ID=67986856

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180032554A Pending KR20190110740A (ko) 2018-03-21 2018-03-21 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR1020207029749A Ceased KR20200123846A (ko) 2018-03-21 2019-03-20 신규한 아릴 또는 헤테로아릴 트리아졸론 유도체 또는 그의 염, 또는 그를 포함하는 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207029749A Ceased KR20200123846A (ko) 2018-03-21 2019-03-20 신규한 아릴 또는 헤테로아릴 트리아졸론 유도체 또는 그의 염, 또는 그를 포함하는 제약 조성물

Country Status (10)

Country Link
US (3) US10562865B2 (enExample)
EP (1) EP3768663A4 (enExample)
JP (2) JP7322052B2 (enExample)
KR (2) KR20190110740A (enExample)
CN (1) CN111886227B (enExample)
AR (1) AR115006A1 (enExample)
AU (1) AU2019237342B2 (enExample)
CA (1) CA3093051A1 (enExample)
TW (1) TWI825079B (enExample)
WO (1) WO2019180644A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022224195A1 (en) * 2021-04-22 2022-10-27 Yuhan Corporation Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
WO2005014530A2 (en) 2003-08-08 2005-02-17 La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
AU2005216955A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2139333A4 (en) 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
EP2822931B1 (en) * 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2013255103B2 (en) 2012-05-02 2016-09-29 Syntara Limited Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
BR112015026631A2 (pt) * 2013-04-25 2017-07-25 Yuhan Corp compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
EA201891674A1 (ru) 2016-02-12 2019-01-31 Фармаксис Лтд. Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
EP3589619A4 (en) 2017-03-02 2020-12-16 Pharmaxis Ltd. LYSYL OXIDASE INHIBITORS, HALOGENOALLYLAMINE PYRAZOLE DERIVATIVES AND THEIR USES
US20200087248A1 (en) 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
AU2018287777B2 (en) 2017-06-20 2020-05-21 Shandong Danhong Pharmaceutical Co., Ltd. SSAO inhibitor
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3114166A1 (en) 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
MX2021003559A (es) 2018-09-28 2021-08-24 Acucela Inc Inhibidores de vap-1.
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
EP3870162A4 (en) 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022224195A1 (en) * 2021-04-22 2022-10-27 Yuhan Corporation Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
CN111886227B (zh) 2023-10-13
TWI825079B (zh) 2023-12-11
US20210147368A1 (en) 2021-05-20
US20200223808A1 (en) 2020-07-16
KR20200123846A (ko) 2020-10-30
US11492335B2 (en) 2022-11-08
CN111886227A (zh) 2020-11-03
AU2019237342A1 (en) 2020-10-01
EP3768663A4 (en) 2021-12-01
TW202003476A (zh) 2020-01-16
AU2019237342B2 (en) 2023-10-19
JP7322052B2 (ja) 2023-08-07
CA3093051A1 (en) 2019-09-26
WO2019180644A1 (en) 2019-09-26
US10899719B2 (en) 2021-01-26
AR115006A1 (es) 2020-11-18
US10562865B2 (en) 2020-02-18
EP3768663A1 (en) 2021-01-27
US20190308944A1 (en) 2019-10-10
JP2023134824A (ja) 2023-09-27
JP2021518377A (ja) 2021-08-02

Similar Documents

Publication Publication Date Title
KR20190110740A (ko) 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US10604532B2 (en) Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases
TWI835945B (zh) 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
CN111886233B (zh) 三唑酮衍生物或其盐以及包含其的药物组合物
KR20100047901A (ko) 암 및 건선 치료에 유용한 복소환 아미드
WO2008141731A2 (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US20220402900A1 (en) 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
JP7263509B2 (ja) 新規な（イソプロピル－トリアゾリル）ピリジニル置換されたベンゾオキサジノン又はベンゾチアジノン誘導体及びその用途
HK40034426A (en) Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
KR20200073499A (ko) 신규의 3,3-다이플루오로알릴아민 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200073503A (ko) 트라이아졸로피리딘-3-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20180321

PG1501 Laying open of application
PC1204 Withdrawal of earlier application forming a basis of a priority claim

Patent event date: 20180321

Comment text: Patent Application

Patent event code: PC12041R01I